- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04573452
Galectin-3 and Placenta Accreta
The Role of Galectin-3 in the Pathogenesis and Prediction of Placenta Accreta
Galectins are a family of carbohydrate-binding proteins that have a high affinity to galactosides, its protein portion is located in the nucleus and the cytoplasm with its carbohydrate recognition domain which has high ability to be glycosylated inside or outside the cell.
They are expressed by vascular endothelium, immune cells (macrophages, neutrophils, and mast cells), uterus, placenta, cardiac muscle, liver, epithelium of the gastrointestinal tract, and many other tissues.
Although some galectins have intracellular functions, the majority of them have extracellular activities, which facilitate their contribution to cell adhesion, cell activation, and inflammation. Galectin-3 (Gal-3) is a unique pentamer of the galectins family and it is involved in both physiological functions; cell growth and differentiation, and pathological conditions; inflammation, fibrosis, and metastasis.
Regarding pregnancy, Gal-3 is proved to participate in angiogenesis, embryo developmental processes, and modulation of maternal immunity.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Assiut, Egypt, 71111
- Women Health Hospital - Assiut university
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Pregnant women between 28-32 weeks.
- Age between 20-40 years.
- Singleton pregnancy.
- Women with suspicion of placenta accreta
- Cases with mild vaginal bleeding or not having any vaginal bleeding.
Exclusion Criteria:
- Women are known to have any medical disorders.
- Patients with known bleeding disorders or on anticoagulant therapy.
- Patients refuse to participate.
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Crossover
- Time Perspectives: Cross-Sectional
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Normal pregnancy group
|
Measurement of Gal-3 in Serum which will be isolated from the blood samples by ELISA (Enzyme-Linked immunosorbent Assay) (R&D Systems, Minneapolis, MN, USA).
Measurement of Gal-3 in Villous and decidual tissues homogenate by ELISA
|
Placenta accreta at 24-32 weeks group
|
Measurement of Gal-3 in Serum which will be isolated from the blood samples by ELISA (Enzyme-Linked immunosorbent Assay) (R&D Systems, Minneapolis, MN, USA).
Measurement of Gal-3 in Villous and decidual tissues homogenate by ELISA
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Galactin 3 level in the blood
Time Frame: 6 weeks
|
measured by ng/ml
|
6 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- G-PA
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Placenta Accreta
-
Kasr El Aini HospitalUnknownPlacenta Accreta in Placenta Previa Anterior
-
Ain Shams Maternity HospitalCompleted
-
Maternal and Child Health Hospital of FoshanWithdrawnPlacenta Accreta SpectrumChina
-
Sohag UniversityRecruiting
-
Necmettin Erbakan UniversityRecruitingPlacenta Accreta, Third TrimesterTurkey
-
Ain Shams UniversityNot yet recruiting
-
Ain Shams UniversityUnknownPlacenta Accreta, Third TrimesterEgypt
-
HaEmek Medical Center, IsraelTechnion, Israel Institute of TechnologyUnknown
-
Cairo UniversityRecruitingPlacenta Accreta Spectrum | Cesarean HysterectomyEgypt
-
Hatem AbuHashimCompletedPlacenta Accreta SpectrumEgypt
Clinical Trials on Galectin-3
-
University Hospital, RouenCompletedGoiter, NodularFrance
-
Recep Tayyip Erdogan University Training and Research...CompletedAnkylosing Spondylitis
-
Necmettin Erbakan UniversityCompletedPlacenta Accreta, Third TrimesterTurkey
-
University of MessinaCompleted
-
Cliniques universitaires Saint-Luc- Université...Terminated
-
Assiut UniversityCompleted
-
Assiut UniversityUnknown
-
Assiut UniversityNot yet recruitingGalectin-3 and Pemphigus
-
Providence Health & ServicesProvidence Cancer Center, Earle A. Chiles Research Institute; Galectin Therapeutics...CompletedMetastatic MelanomaUnited States
-
Danish Headache CenterCompleted